RU2290403C2 - Ингибиторы vla-4 - Google Patents

Ингибиторы vla-4 Download PDF

Info

Publication number
RU2290403C2
RU2290403C2 RU2003123115/04A RU2003123115A RU2290403C2 RU 2290403 C2 RU2290403 C2 RU 2290403C2 RU 2003123115/04 A RU2003123115/04 A RU 2003123115/04A RU 2003123115 A RU2003123115 A RU 2003123115A RU 2290403 C2 RU2290403 C2 RU 2290403C2
Authority
RU
Russia
Prior art keywords
group
mmol
compound
unsubstituted
mixture
Prior art date
Application number
RU2003123115/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2003123115A (ru
Inventor
Ацуси НАКАЯМА (JP)
Ацуси НАКАЯМА
Нобуо МАТИНАГА (JP)
Нобуо МАТИНАГА
Йосиюки ЙОНЕДА (JP)
Йосиюки ЙОНЕДА
Юити СУГИМОТО (JP)
Юити СУГИМОТО
Дзун ТИБА (JP)
Дзун ТИБА
Тосиюки ВАТАНАБЕ (JP)
Тосиюки ВАТАНАБЕ
Син ИЙМУРА (JP)
Син ИЙМУРА
Original Assignee
Дайити Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Лтд. filed Critical Дайити Фармасьютикал Ко., Лтд.
Publication of RU2003123115A publication Critical patent/RU2003123115A/ru
Application granted granted Critical
Publication of RU2290403C2 publication Critical patent/RU2290403C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
RU2003123115/04A 2000-12-28 2001-12-28 Ингибиторы vla-4 RU2290403C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000402890 2000-12-28
JP2000-402890 2000-12-28
JP2001149923 2001-05-18
JP2001-149923 2001-05-18

Publications (2)

Publication Number Publication Date
RU2003123115A RU2003123115A (ru) 2005-03-27
RU2290403C2 true RU2290403C2 (ru) 2006-12-27

Family

ID=26607210

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003123115/04A RU2290403C2 (ru) 2000-12-28 2001-12-28 Ингибиторы vla-4

Country Status (16)

Country Link
US (1) US7157487B2 (Direct)
EP (1) EP1346982B1 (Direct)
JP (1) JP4212358B2 (Direct)
KR (1) KR100884877B1 (Direct)
CN (1) CN100471838C (Direct)
AR (1) AR035218A1 (Direct)
AT (1) ATE524441T1 (Direct)
AU (1) AU2002219555B2 (Direct)
BR (1) BR0116608A (Direct)
CA (1) CA2430978C (Direct)
IL (1) IL156064A0 (Direct)
MX (1) MXPA03005838A (Direct)
NO (1) NO326014B1 (Direct)
RU (1) RU2290403C2 (Direct)
TW (1) TWI312779B (Direct)
WO (1) WO2002053534A1 (Direct)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
SI1549638T1 (sl) 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
US7345179B2 (en) * 2003-05-09 2008-03-18 Daiichi Pharmaceutical Co., Ltd. Process for producing pyrrolidine derivative
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
EP1698621A4 (en) * 2003-12-26 2008-11-19 Daiichi Seiyaku Co PROCESS FOR PREPARING A PYRROLIDINE DERIVATIVE
JPWO2005063678A1 (ja) * 2003-12-26 2007-12-20 第一三共株式会社 フェニル酢酸誘導体の製造方法
ES2530056T3 (es) * 2004-03-24 2015-02-26 Shire Orphan Therapies Gmbh Nuevos compuestos para la inhibición de la angiogénesis y su uso
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN101022802A (zh) 2004-07-22 2007-08-22 Ptc医疗公司 用于治疗丙型肝炎的噻吩并吡啶化合物
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
JP5107724B2 (ja) * 2005-12-13 2012-12-26 第一三共株式会社 Ｖｌａ−４阻害薬
AU2007347115A1 (en) 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) * 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
WO2010006072A2 (en) * 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
ES2570429T3 (es) 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
SI2376485T1 (en) 2008-12-19 2018-04-30 Vertex Pharmaceuticals Incorporated PIRAZINE DERIVATIVES USE AS ATR KINASE INHIBITORS
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
CA2765044A1 (en) 2009-06-09 2010-12-16 California Capital Equity, Llc Benzyl substituted triazine derivatives and their therapeutical applications
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
JP2012529530A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ヘッジホッグシグナル伝達の阻害剤としての、イソキノリン、キノリン及びキナゾリン誘導体
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California IRE1 MODULATION
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017009513A2 (pt) * 2014-11-06 2018-02-06 Basf Se utilização de um composto heterobicíclico, utilização dos compostos i, compostos, composição agrícola ou veterinária, método para o combate ou controle de pragas, método para a proteção de culturas e sementes
AU2016276316B2 (en) 2015-06-09 2020-01-23 Abbvie Inc. Nuclear receptor modulators
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
KR102652797B1 (ko) 2018-10-30 2024-04-02 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린의 억제를 위한 화합물
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
BR112022025037A2 (pt) 2020-06-10 2023-02-14 Aligos Therapeutics Inc Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
EP4284947A1 (en) 2021-01-29 2023-12-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
MX2024000299A (es) 2021-07-09 2024-03-14 Aligos Therapeutics Inc Compuestos antivirales.
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181658A (en) * 1977-02-18 1980-01-01 Hoechst Aktiengesellschaft Certain nicotinamido-n-benzoic acid derivatives
US4221815A (en) * 1975-01-03 1980-09-09 Hoechst Aktiengesellschaft Benzoic acids, their derivatives and process for preparing them
EP0023569A1 (de) * 1979-07-13 1981-02-11 Dr. Karl Thomae GmbH Carbonsäure-Derivate, deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0585155A1 (fr) * 1992-07-28 1994-03-02 Adir Et Compagnie Peptides dérivés de trifluorométhylcétones ayant une actovoté inhibants d'élastase leucocytaire humaine (HLE), leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO1995030673A1 (en) * 1994-05-05 1995-11-16 British Technology Group Limited Anti-cancer compounds containing cyclopentaquinazoline ring
WO1996004267A1 (en) * 1994-08-01 1996-02-15 Laboratorios Menarini S.A. Naphthalene amides having leukotriene-antagonistic action
WO1996022966A1 (en) * 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1997002024A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
WO1997022619A2 (en) * 1995-12-20 1997-06-26 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1998022430A1 (en) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
WO1999043672A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase a2
RU98101915A (ru) * 1995-07-07 1999-12-10 Берингер Маннхайм ГмбХ Новые производные оксазолидинона, способ их получения, а также лекарственные средства, содержащие эти соединения
WO1999064392A1 (en) * 1998-06-08 1999-12-16 Ajinomoto Co., Inc. Benzamidine derivative
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
WO2000018770A1 (en) * 1998-09-30 2000-04-06 Glaxo Group Limited Pyrrolopyrrolone derivatives as antiviral agents
WO2000040088A1 (en) * 1999-01-07 2000-07-13 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
WO2000066119A1 (en) * 1999-05-05 2000-11-09 Merck & Co., Inc. Novel prolines as antimicrobial agents
JP2000344666A (ja) * 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184658A (en) 1978-02-13 1980-01-22 General Electric Company Cushion mount for prime mover
JPS60181081A (ja) 1984-02-29 1985-09-14 Kaken Pharmaceut Co Ltd 新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja) * 1990-09-03 1992-04-14 Otsuka Pharmaceut Co Ltd 置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja) 1991-08-13 1993-02-23 Wakamoto Pharmaceut Co Ltd ヘテロ環置換テトラゾール−１−酢酸誘導体
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
HUP0101701A3 (en) 1997-12-23 2003-02-28 Aventis Pharma Ltd West Mallin Substituted betha-alanines and pharmaceutical compositions comprising them
WO1999061421A1 (en) 1998-05-28 1999-12-02 Biogen, Inc. A NOVEL VLA-4 INHIBITOR: oMePUPA-V
DE69928667T2 (de) 1998-06-30 2006-08-10 Pfizer Products Inc., Groton Nicht-peptidische Inhibitoren von VLA-4-abhängiger Zellbindung für die Behandlung von entzündlichen, autoimmun-und respiratorischen Krankheiten und Atemstörungen
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
TR200100588T2 (tr) 1998-08-26 2001-08-21 Pharma Limited Aventis Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.
PT1153017E (pt) 1999-02-16 2006-07-31 Aventis Pharma Ltd Compostos biciclicos e sua utilizacao como ligandos do receptor de integrina
HK1044937A1 (zh) 1999-04-12 2002-11-08 Aventis Pharma Limited 作为整联蛋白拮抗物的取代的双环杂芳基化合物
HK1042293A1 (zh) 1999-05-05 2002-08-09 Aventis Pharma Limited 取代的吡咯烷作為細胞粘合抑制物
WO2000068213A1 (en) 1999-05-05 2000-11-16 Aventis Pharma Limited Substituted bicyclic compounds
DE60009480T2 (de) 1999-05-05 2005-09-01 Aventis Pharma Ltd., West Malling Harnstoffe als modulatoren der zelladhäsion
US6756378B2 (en) * 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
JP2003503350A (ja) 1999-06-30 2003-01-28 第一製薬株式会社 Ｖｌａ−４インヒビター化合物
CA2380817A1 (en) 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
AU2155001A (en) 1999-11-10 2001-06-06 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
HUP0203897A3 (en) * 1999-12-28 2005-06-28 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0001346D0 (en) 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
AU2001235806A1 (en) 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CN1620433A (zh) 2000-07-19 2005-05-25 霍夫曼-拉罗奇有限公司 作为内皮肽转化酶抑制剂的吡咯烷衍生物
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221815A (en) * 1975-01-03 1980-09-09 Hoechst Aktiengesellschaft Benzoic acids, their derivatives and process for preparing them
US4181658A (en) * 1977-02-18 1980-01-01 Hoechst Aktiengesellschaft Certain nicotinamido-n-benzoic acid derivatives
EP0023569A1 (de) * 1979-07-13 1981-02-11 Dr. Karl Thomae GmbH Carbonsäure-Derivate, deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0585155A1 (fr) * 1992-07-28 1994-03-02 Adir Et Compagnie Peptides dérivés de trifluorométhylcétones ayant une actovoté inhibants d'élastase leucocytaire humaine (HLE), leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO1995030673A1 (en) * 1994-05-05 1995-11-16 British Technology Group Limited Anti-cancer compounds containing cyclopentaquinazoline ring
WO1996004267A1 (en) * 1994-08-01 1996-02-15 Laboratorios Menarini S.A. Naphthalene amides having leukotriene-antagonistic action
WO1996022966A1 (en) * 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1997002024A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
RU98101915A (ru) * 1995-07-07 1999-12-10 Берингер Маннхайм ГмбХ Новые производные оксазолидинона, способ их получения, а также лекарственные средства, содержащие эти соединения
WO1997022619A2 (en) * 1995-12-20 1997-06-26 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO1998022430A1 (en) * 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING b-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
WO1999043672A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase a2
WO1999064392A1 (en) * 1998-06-08 1999-12-16 Ajinomoto Co., Inc. Benzamidine derivative
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
WO2000018770A1 (en) * 1998-09-30 2000-04-06 Glaxo Group Limited Pyrrolopyrrolone derivatives as antiviral agents
WO2000040088A1 (en) * 1999-01-07 2000-07-13 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
JP2000344666A (ja) * 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤
WO2000066119A1 (en) * 1999-05-05 2000-11-09 Merck & Co., Inc. Novel prolines as antimicrobial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.PALOMER et al, Derivation of Pharmacophore and CoMFA Models for Leukotriene D4 Receptor Antagonists of the Quinolinyl(bridged)aryl Series, Journal of Medicinal Chemistry, 2000, том 43, №3, стр.392-400. *

Also Published As

Publication number Publication date
HK1081545A1 (zh) 2006-05-19
IL156064A0 (en) 2003-12-23
WO2002053534A1 (en) 2002-07-11
EP1346982B1 (en) 2011-09-14
EP1346982A4 (en) 2005-08-10
TWI312779B (Direct) 2009-08-01
JP4212358B2 (ja) 2009-01-21
CN100471838C (zh) 2009-03-25
CA2430978A1 (en) 2002-07-11
US20040110945A1 (en) 2004-06-10
AU2002219555B2 (en) 2006-11-30
NO326014B1 (no) 2008-09-01
CA2430978C (en) 2012-05-15
NO20032994D0 (no) 2003-06-27
JPWO2002053534A1 (ja) 2004-04-30
NO20032994L (no) 2003-08-27
CN1483024A (zh) 2004-03-17
KR100884877B1 (ko) 2009-02-23
US7157487B2 (en) 2007-01-02
EP1346982A1 (en) 2003-09-24
MXPA03005838A (es) 2003-09-10
BR0116608A (pt) 2004-06-29
RU2003123115A (ru) 2005-03-27
KR20030067730A (ko) 2003-08-14
WO2002053534A8 (en) 2002-09-19
AR035218A1 (es) 2004-05-05
ATE524441T1 (de) 2011-09-15
HK1060726A1 (zh) 2004-08-20

Similar Documents

Publication Publication Date Title
RU2290403C2 (ru) Ингибиторы vla-4
AU2021381437B2 (en) Novel spiropyrrolidine derived antiviral agents
KR101799007B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설폰아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물
JP4101053B2 (ja) プロリン誘導体及びその医薬用途
KR20150018788A (ko) 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘
AU2015314851B2 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
TW201823208A (zh) N－醯基胺基酸化合物及其使用方法
JP2012524760A (ja) オレキシンアンタゴニストとして使用される３−アザビシクロ［４．１．０］ヘプタン
KR20100071048A (ko) Ｄｇａｔ１ 억제제로서의 옥사디아졸- 및 옥사졸-치환된 벤즈이미다졸- 및 인돌-유도체
WO2012020749A1 (ja) トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物
KR20040033048A (ko) 티아졸리딘 유도체 및 이의 약학적 용도
AU2018326734B2 (en) Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists
AU2010261791A1 (en) Anthelmintic agents and their use
JPWO2005121135A1 (ja) Ｖｌａ−４阻害薬
KR20110025970A (ko) 트롬빈 억제제로서 사용하기 위한 신규 복소환 카복스아미드
JP4704914B2 (ja) α−アミノ酸誘導体及びその医薬用途
KR20180050408A (ko) 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제
CN100396680C (zh) 极迟抗原-4抑制剂
WO2024233639A2 (en) Stat degraders and uses thereof
WO2025114399A1 (en) Flavivirus inhibitors
HK1081545B (en) Vla-4 inhibitors
HK1060726B (zh) Vla-4抑制剂